enGene Holdings Inc.: 5%+ holders

As of November 7, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of enGene Holdings Inc. The largest reported stake is Perceptive Advisors LLC's, at 9.99%. 17 filings are on record since November 14, 2025 (Schedule 13G/A, August 14, 2026).

ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies ↓

Sell to companies like enGene Holdings Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 6,899,803 · Sole dispositive: 0 · Shared dispositive: 6,899,803 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Venrock Healthcare Capital Partners III, L.P. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-13 · Reporting person: Invus Public Equities, L.P. · Sole voting: 5,481,984 · Shared voting: 0 · Sole dispositive: 5,481,984 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13
• Filing 2026-08-12 · Reporting person: Blue Owl Capital Holdings LP · Sole voting: 511,177 · Shared voting: 0 · Sole dispositive: 511,177 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-12

enGene Holdings Inc. has 17 Schedule 13D or 13G filings on record since 2025-11-14. 4 holders' latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: 2 filings or notices, latest 2026-06-18 (layoff filings and notices).

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind enGene Holdings Inc. and the warning signs.

See enGene Holdings Inc.'s free Snapshot Watch enGene Holdings Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on enGene Holdings Inc. and the records around it.

enGene Holdings Inc. elsewhere on the record

• Leadership changes Jul 2026
• Layoff notices Jun 2026
• Who owns it

Companies that share a holder

• ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies: Karyopharm Therapeutics Inc. (Oct 2026), Athira Pharma, Inc. (Aug 2026), OnKure Therapeutics, Inc. (Apr 2026)
• Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026)
• Blue Owl Capital Holdings LP also filed stake reports on 10 other companies: Context Therapeutics Inc. (Aug 2026), Aktis Oncology, Inc. (May 2026), ImageneBio, Inc. (May 2026)

Want the whole picture on enGene Holdings Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on enGene Holdings Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on enGene Holdings Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   20 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies enGene Holdings Inc. by CUSIP 29286M105 and gives its principal executive office as 4868 Rue Levy, Suite 220, Saint-Laurent (SCHEDULE 13G/A, 2026-08-14).

What the percentages are based on

As of June 30, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page.Raymond Debbane, SCHEDULE 13G/A, 2026-08-13

The percentages set forth herein are calculated based upon 66,989,466 shares of Common Stock outstanding as of June 9, 2026 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 filed with the Securities and Exchange Commission on June 15, 2026..Anders Hove, SCHEDULE 13G, 2026-07-22

Timeline

Swipe the table sideways to see every column.

Questions about who owns enGene Holdings Inc.

Who owns enGene Holdings Inc.?

On this page, 4 holders' latest ownership filings report 5% or more of enGene Holdings Inc.: Perceptive Advisors LLC (9.99%, Schedule 13G/A, filed 2026-08-14), BML Investment Partners, L.P. (9.95%, Schedule 13G/A, filed 2026-05-14), Raymond Debbane (9.3%, Schedule 13G/A, filed 2026-08-13) and Anders Hove (5%, Schedule 13G, filed 2026-07-22).

Who are the largest shareholders of enGene Holdings Inc.?

By the share each holder's latest filing reports, the largest holders of enGene Holdings Inc. on this page are Perceptive Advisors LLC (9.99%), BML Investment Partners, L.P. (9.95%) and Raymond Debbane (9.3%).

When did Perceptive Advisors LLC buy into enGene Holdings Inc.?

The filings give report dates, not purchase dates. The earliest filing from Perceptive Advisors LLC on this page is the Schedule 13G, filed 2025-11-18, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for enGene Holdings Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for enGene Holdings Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when enGene Holdings Inc. is mentioned again
• Find former enGene Holdings Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes